Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CCZ1 CRISPR/Cas9 KO Plasmid (h): sc-417084
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CCZ1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CCZ1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CCZ1 Antibody (B-7): sc-514290
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CCZ1 CRISPR/Cas9 KO Plasmid (h) | sc-417084 | 20 µg | $397.00 |
Overview
CCZ1B encodes the CCZ1 protein, a core component of the CCZ1–MON1 guanine nucleotide exchange factor complex that activates RAB7 to coordinate late endosome maturation and endosome–lysosome fusion. Through regulation of RAB7-dependent membrane trafficking, CCZ1 supports lysosomal delivery and turnover of internalized receptors and cargo, influencing autophagy–lysosome flux and cellular proteostasis. Perturbation of this pathway can disrupt organelle homeostasis, alter signaling receptor downregulation, and affect responses to metabolic and proteotoxic stress. Accordingly, CCZ1B is of interest in studies of neurodegeneration, cancer cell adaptation, and immune cell function where endolysosomal trafficking and autophagy are frequently remodeled.
CCZ1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CCZ1B gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CCZ1B together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CCZ1B open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CCZ1 protein expression.
This CRISPR knockout system enables efficient generation of CCZ1B-deficient cell models for investigation of CCZ1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CCZ1B exon(s) critical for CCZ1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CCZ1B genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CCZ1 CRISPR/Cas9 KO Plasmid (h) and CCZ1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CCZ1B locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CCZ1 HDR Plasmid (h) and CCZ1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CCZ1B homology arms to support homology-directed repair at defined CCZ1B target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.